Compass Therapeutics, Inc. $CMPX Shares Bought by Sofinnova Investments Inc.

Sofinnova Investments Inc. raised its stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 65.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,365,446 shares of the company’s stock after purchasing an additional 1,336,560 shares during the quarter. Sofinnova Investments Inc. owned about 1.89% of Compass Therapeutics worth $18,072,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Suvretta Capital Management LLC boosted its holdings in shares of Compass Therapeutics by 97.2% in the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after purchasing an additional 6,951,666 shares during the last quarter. Monashee Investment Management LLC boosted its holdings in shares of Compass Therapeutics by 657.6% in the 3rd quarter. Monashee Investment Management LLC now owns 1,250,000 shares of the company’s stock valued at $4,375,000 after purchasing an additional 1,085,000 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $4,104,000. NEXTBio Capital Management LP acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $5,982,000. Finally, Royce & Associates LP acquired a new position in shares of Compass Therapeutics in the 4th quarter valued at $1,536,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

Compass Therapeutics Trading Up 0.5%

NASDAQ:CMPX opened at $2.04 on Tuesday. The firm has a market capitalization of $367.38 million, a price-to-earnings ratio of -4.98 and a beta of 0.89. The firm’s fifty day simple moving average is $3.10 and its 200 day simple moving average is $4.74. Compass Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, May 5th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). On average, analysts predict that Compass Therapeutics, Inc. will post -0.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CMPX. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a report on Monday, April 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Monday, April 20th. William Blair reiterated an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Citigroup restated a “market outperform” rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Finally, Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a report on Monday, June 1st. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $12.91.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.